Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome

<p>Significant activation of key developmental and metabolic gene pathways and potential compensatory mechanism with ANAVEX®2-73 in Rett syndrome patients Heatmap Heatmap NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) &#8212; Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including [&#8230;]</p>
<p>The post <a href="https://forextv.com/top-news/anavex-announces-first-entire-clinical-gene-pathway-data-of-anavex2-73-from-avatar-study-in-patients-with-rett-syndrome/">Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>